Stock Financial Ratios, Dividends, Split History

WHLR / Wheeler Real Estate Investment Trust, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)32.03
Enterprise Value ($M)35.44
Book Value ($M)60.53
Book Value / Share6.68
Price / Book0.50
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 8,744,189
Common Shares Outstanding 8,946,399
Preferred Stock Shares Outstanding 562
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.20
Return on Assets (ROA)-0.03
Return on Equity (ROE)-0.13
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Other Sales Revenue Net1,521,000.00
Property Management Fee Revenue927,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Operating Income0.54
Net Income-12.78
Earnings Per Share Basic And Diluted-2.54
Cash Flow Statement (mra) ($M)
Cash From Operations24.76
Cash from Investing-2.98
Cash from Financing-2.98
Identifiers and Descriptors
Central Index Key (CIK)1527541
Related CUSIPS

Split History

Stock splits are used by Wheeler Real Estate Investment Trust, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

The State Of REITs: May 2018 Edition

2018-05-11 seekingalpha
The REIT rally that began in March grew stronger in April as REITs again outperformed the broader market. (11-1)

Wheeler Real Estate Investment's (WHLR) CEO Dave Kelly on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Wheeler Real Estate Investment Trust (NASDAQ:WHLR) Q1 2018 Earnings Conference Call May 9, 2018 10:00 AM ET (9-0)

BRIEF-Wheeler Real Estate Investment Trust Announces Changes To Its Board Of Directors

2018-04-16 reuters

The State Of REITs: April 2018 Edition

2018-04-06 seekingalpha
REITS underperformed the S&P 500 in Q1, but outperformed in March as the broader market continued to sell off. (6-0)

5 Dividends We Need To Talk About In 2018

2018-03-27 seekingalpha
Great! That means more discounts for investors looking to allocate their capital. Buy-and-hold investors should be looking for investments that will outperform over the long term. A bad investment can have a good year, but it’s hard for them to have 10 good years in a row. For instance, Wheeler Real Estate Investment Trust (WHLR) didn’t have a “bad” year in 2016. However, they are and were a terrible investment. (18-0)

CUSIP: 963025101